Copyright © 2021. Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

Analyytikko

Viimeisin video

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
17.5.
2021

 Faron Pharmaceuticals Oy

("Faron" or the "Company")

Tiedotteet
14.5.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron secures U.S. rights to patent related to Traumakine 

Company announcement, 14 May 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033.

Tiedotteet
10.5.
2021

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

Tiedotteet
29.4.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Grant of options

Company announcement, 29 April 2021 at 14.45 (EEST)

Tiedotteet
23.4.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Results of the Annual General Meeting and Decisions of the Board of Directors

Company announcement, 23 April 2021 at 15:45 p.m. (EEST)

TURKU, FINLAND - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place at the premises of Inderes Oy in Helsinki, Finland today, 23 April 2021. The AGM approved all the proposals of the board of directors ("Board") and its committees, set out in the notice of the AGM published on 25 March 2021.

Tiedotteet
23.4.
2021

Faron Pharmaceuticals Oy

 

("Faron" or the "Company")

Board Change

Company announcement, 23 April 2021 at 15:45 EET

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Anne Whitaker as a Non-Executive Director of the Company following the passing of all resolutions put to shareholders of the Company at the AGM held earlier today. 

Tiedotteet
29.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Appointment of a Broker

 

Company announcement, 29 March 2021 at 9.00 AM (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Peel Hunt LLP as the Company's sole Broker with effect from today.

 

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

Tiedotteet
25.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Exercise of options

Issue of equity

Company announcement, 25 March 2020 at 9.45 AM (EET)

 

Tiedotteet
25.3.
2021

NOTICE OF Faron pharmaceuticals LTD's Annual GENERAL MEETING

Tiedotteet
25.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron's Annual Report 2020 published

Company announcement, 25 March 2021 at 9.15 AM (EET)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2020 has been published today.

Faron Pharmaceuticals

ipo